Automatic volumetric diagnosis of hepatocellular carcinoma based on four-phase CT scans with minimum extra information

Yating Ling¹, Shihong Ying², Lei Xu³, Zhiyi Peng², Xiongwei Mao⁴, Zhang Chen⁵, Jing Ni², Qian Liu¹, Shaolin Gong² and Dexing Kong¹*

¹School of Mathematical Sciences, Zhejiang University, Hangzhou, China; ²Department of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China; ³Computational Imaging and Digital Medicine, Zhejiang Qiushi Institute of Mathematical Medicine, Hangzhou, China; ⁴Department of Radiology, The Hospital of Zhejiang University, Hangzhou, China; ⁵Department of Radiology, Jiangcun Community Health Service Center, Hangzhou, China

Summary: We built a deep-learning based model for diagnosis of HCC with typical images from four-phase CT and MEI, demonstrating high performance and excellent efficiency.

Objectives: The aim of this study was to develop a deep-learning-based model for the diagnosis of hepatocellular carcinoma.

Materials and methods: This clinical retrospective study uses CT scans of liver tumors over four phases (non-enhanced phase, arterial phase, portal venous phase, and delayed phase). Tumors were diagnosed as hepatocellular carcinoma (HCC) and non-hepatocellular carcinoma including cyst, hemangioma (HA), and intrahepatic cholangiocarcinoma (ICC). A total of 601 liver lesions from 479 patients (56 years ± 11 [standard deviation]; 350 men) are evaluated between 2014 and 2017 for a total of 315 HCCs and 286 non-HCCs including 64 cysts, 178 HAs, and 44 ICCs. A total of 481 liver lesions were randomly assigned to the training set, and the remaining 120 liver lesions constituted the validation set. A deep learning model using 3D convolutional neural network (CNN) and multilayer perceptron is trained based on CT scans and minimum extra information (MEI) including text input of patient age and gender as well as automatically extracted lesion location and size from image data. Fivefold cross-validations were performed using randomly split datasets. Diagnosis accuracy and efficiency of the trained model were compared with that of the radiologists using a validation set on which the model showed matched performance to the fivefold average. Student’s t-test (T-test) of accuracy between the model and the two radiologists was performed.

Results: The accuracy for diagnosing HCCs of the proposed model was 94.17% (113 of 120), significantly higher than those of the radiologists, being 90.83% (109 of 120, p-value = 0.018) and 83.33% (100 of 120, p-value = 0.002). The average time analyzing each lesion by our proposed model on one Graphics
Processing Unit was 0.13 s, which was about 250 times faster than that of the two radiologists who needed, on average, 30 s and 37.5 s instead.

**Conclusion:** The proposed model trained on a few hundred samples with MEI demonstrates a diagnostic accuracy significantly higher than the two radiologists with a classification runtime about 250 times faster than that of the two radiologists and therefore could be easily incorporated into the clinical workflow to dramatically reduce the workload of radiologists.

**KEYWORDS**
computed tomography, diagnosis, hepatocellular carcinoma, deep learning, artificial intelligence

**Highlights**

1. The accuracy for diagnosing hepatocellular carcinomas of the proposed model and two radiologists was 94.17% (113 of 120), 90.83% (109 of 120, \( p = 0.018 \)), and 83.33% (100 of 120, \( p = 0.002 \)), showing significant differences.
2. The average time analyzing each lesion by our proposed model was 0.13 s, which was hundred times faster than the two radiologists.
3. The proposed model can serve as a quick and reliable "second opinion" for radiologists.

**Introduction**

Hepatocellular carcinoma (HCC) is the third most common malignancy worldwide, with incidence rates continuing to rise (1). CT slices often serve as an important assistive diagnostic tool for HCCs (2). According to the American Association for the Study of Liver Disease (AASLD) and the Liver Imaging Reporting and Data System (LI-RADS) reported by the American College of Radiology, the hallmark diagnostic characteristics of HCC on multi-phasic CT slices are arterial phase hyper-enhancement followed by washout appearance in the portal-venous and/or delayed phases (3, 4). Four-phase CT slices that contain non-enhanced, arterial, portal-venous, and delayed phases are recommended as the clinical standard.

However, ensuring the diagnosis performance of a computer-aided system equivalent to that of radiologists with minimum extra information (MEI) about the patients for instance including only basic data about age and gender on a relatively small dataset based on four-phase CT images is still challenging in order to relieve the radiologists’ workload as well as to improve the diagnosis throughout (5).

Machine learning algorithms have been widely applied in the radiological classification of various diseases and may potentially address this challenge (6–8). Recently, among different machine learnings, deep learning with convolutional neural network (CNN) have achieved state-of-the-art performances with respect to pattern recognition of images for various organs and tissues (9–15). It has been verified that CNN-based methods show high diagnostic performance in differentiation of tumors (16–20), but with most of them being limited to 2D slices, which needs manual selection. Meanwhile, it does not take advantage of 3D information that can potentially improve the diagnostic performances (21–25). Moreover, previous works (16, 17, 19, 25) for liver tumor diagnosis use three-phase CT slices, namely, non-enhanced phase, arterial phase, and transitional phase, which is between the portal-venous phase and the delay phase. However, hypointensity in the transitional phase does not qualify as "washout", which is considered a strong predictor and major criterion of HCC (3, 4). Therefore, in this study, we propose a 3D residual network (ResNet) as our basis network to explore the 3D structural information with four-phase CT images for tumor diagnosis (26).

Typically, high-performing CNN requires training on large datasets, which unfortunately are difficult to obtain especially in the medical field. As an alternative to large datasets, highly complicated clinical data collected from multi-modalities are incorporated to the CNN models (27, 28). Numerous works have discussed the auxiliary role of clinical data for HCC diagnosis, including, for example, alpha fetoprotein as a serological marker for HCCs since the 1960s (29), hepatitis B virus infection (30),

**Abbreviations:** HCC, hepatocellular carcinoma; HA, hemangioma; ICC, intrahepatic cholangiocarcinoma; CNN, convolutional neural network; ResNet, residual network; MEPaLe model, model fused with minimum extra information about patient and lesion; MEI, minimum extra information; T-test, Student’s t-test.
and medical record of having non-alcoholic fatty liver diseases (31). However, those clinical data often require additional examinations. Therefore, it would be better if one only needs the patient’s basic information, such as age and gender, which is crucial for liver tumor diagnosis (32–34) and makes full use of the spatial morphological information of local lesions that may be lost or downplayed in image processing.

In summary, our study aims to develop a fast-processing deep learning algorithm that exploits 3D structural with dynamic contrast information from four-phase CT scans and requires minimum patient information, i.e., age and gender, as well as automatically extracted lesion location and size from image data based on a relatively small dataset. We name the algorithm as the MExPaLe model (Model Fused with Minimum Extra Information about Patient and Lesion). The main contributions of this work are as follows:

- We propose a 3D model that feeds volumetric data as input instead of 2D CT slices to improve the diagnosis performance.
- We evaluate the diagnosis results of the basic model, which only uses non-enhanced phase CT images as input and enhanced model, which adds contrast-enhanced phase images as additional inputs. We experimentally confirm the necessity of using enhanced contrast agents in clinical workflow.
- The MExPaLe model fuses CNN and multilayer perceptron to incorporate two different modalities: image data and text data. The text data contain only information of patient gender and age, appended with the spatial morphological information of local lesions.
- The MExPaLe model demonstrates high performance and excellent efficiency. The accuracy and time efficiency for liver diagnosis of the proposed model are significantly higher than the two radiologists.

This paper is organized into four sections. In Section 2, we first describe the data collected in our paper, then introduce three models in this study, and finally the evaluation metrics have been presented. Section 3 presents the results of our models and the comparison with other models and two radiologists. The discussion is provided in Section 4.

## Materials and methods

This retrospective clinical study was approved by the review board, and the requirement for written informed consent was waived. Patients diagnosed as benign and HA through 1-year follow-up in 2018 while diagnosed as HCC and ICC after surgery or biopsy were enrolled between 2014 and 2017. Individuals without four-phase CT images were excluded, shown in Figure 1. Ultimately, a total of 601 lesions (315 HCCs) from 479 patients were selected. The details are presented in Table 1.

### Data preprocessing

All CT slices were obtained with PHILIPS Brilliance iCT 256 scanner (Philips Healthcare, Netherlands). Contrast enhancement materials (Ultravist 300-3440, Bayer Schering Pharma AG, Germany) were injected. These four-phase CT images, stored as DICOM files, have a size of 512×512, and the thickness of each slice is 3 or 5 mm. The target lesions were manually labeled with 3D bounding boxes by a radiologist with 10 years of experience (XM) using software designed by Peng et al. (35) and revised if needed by a radiologist with 38 years of experience (ZY). The images were further processed by code written in the programming language Python 3.6 (https://www.python.org). We first reshaped the four-phase images to 1×1×1 mm using the cubic spline interpolation method and extracted the lesions and the surrounding 5-mm pixels by the bounding boxes. Then, the cropped 3D images were resized to a resolution of 64×64×64 voxels. The images were finally randomly selected to comprise the test data using fivefold cross-validation with the remaining images being the training data. Table 2 summarizes the distribution of each experiment.

The gender and age of the patients are the basic information recorded in the clinical system. Their contributions to HCC and non-HCC including benign, HA, and ICC diagnosis were evaluated in this study. In addition, the location and size of the lesions are inevitably lost during the common data preprocessing procedure. Therefore, we recorded the maximum normalized size and the relative location of the bounding box as our spatial morphological information during the data preprocessing. We also evaluated the contribution of spatial morphological information for HCC diagnosis.

### Models

The model was built using Keras 2.2.4 (https://keras.io/) with a Tensorflow backend 1.5.0 (https://www.tensorflow.org/). For a baseline, we built a deep learning model based on the structure of 3D ResNet with 14 layers (13 convolutional layers and 1 global average pooling layer). Filter size of the first convolution layer is 5×5×5, and the following filter sizes are 3×3×3. The filter size of the global average pooling layer is 2×2×2. The basic model only uses non-enhanced phase CT images as input while the enhanced model adds contrast-enhanced phase images as additional input. For the basic and enhanced model, a fully connected layer is added following the 3D ResNet structure, whose output value represents the probability belonging to the corresponding class. The MExPaLe model contains two
Among 492 participants enrolled in our study, CT is missing in 13 participants.

Crop and resize images around each lesion.

Randomly divide lesions into 5 groups. Each iteration chooses a different group as the test data.

The model is trained on the training cohort.

The model is validated on a test cohort.

The performance of model is compared with two radiologists on the same dataset for one iteration.

**TABLE 1** Patient characteristics and demographics.

| Patient characteristics | HCC  | Cyst | HA   | ICC  | Total |
|-------------------------|------|------|------|------|-------|
| Number of patients      | 312  | 37   | 107  | 41   | 479   |
| Number of lesions       | 315  | 64   | 178  | 44   | 601   |
| Age at imaging (mean ± std) | 58 ± 11 | 58 ± 7 | 50 ± 10 | 59 ± 10 | 56 ± 11 |
| Gender                  |      |      |      |      |       |
| Male                    | 268  | 28   | 41   | 29   | 350   |
| Female                  | 44   | 9    | 66   | 12   | 129   |

HCC, hepatocellular carcinoma; HA, hemangioma; ICC, intrahepatic cholangiocarcinoma; std, standard deviation.

**TABLE 2** Distribution of the fivefold cross-validation dataset.

| Experiment | E1   | E2   | E3   | E4   | E5   |
|------------|------|------|------|------|------|
| Training data |      |      |      |      |      |
| HCC        | 480  | 481  | 481  | 481  | 481  |
| Non-HCC    | 252  | 252  | 252  | 252  | 252  |
| Test data  |      |      |      |      |      |
| HCC        | 228  | 229  | 229  | 229  | 229  |
| Non-HCC    | 121  | 120  | 120  | 120  | 120  |
| Total      | 601  | 601  | 601  | 601  | 601  |

HCC, hepatocellular carcinoma; E1–E5 denote five sets of experiments.
pathways: the CT pathway and the MEI pathway. The CT pathway has the same design as the aforementioned 3D ResNet structure but with the final classification layer removed. The MEI contains the patient age and gender extracted from the DICOM files and the relative size and location of lesions extracted from the CT pathway. MEI is text information; thus, we used a multilayer perceptron model containing two fully connected layers for this pathway. In our model, after the high-level features are flattened, image features and the text features are concatenated together. Finally, the concatenated feature vector is connected to a fully connected layer for final classification. The overview of the proposed method is shown in Figure 2.

All models use rectified linear units to help models learn non-linear features. These are used in conjunction with batch normalization and dropout to reduce overfitting. Each model was trained with a stochastic gradient descent optimizer using minibatches of eight samples. Each model was trained for 80 epochs. The training rate was initially set to 0.01, and it was reduced by half every 10 epochs.

The performance of the MExPaLe model was compared with two certified radiologists. The two radiologists (HY, with 21 years of imaging experience, and HC, with 16 years of imaging experience) did not take part in the data annotation process and were blinded to the lesion selection. For fair comparison and to simultaneously mimic the real working scenario as closely as possible, we provided four-phase CT DICOM data and the corresponding lesion 3D bounding boxes to both the MExPaLe model and radiologists. The test set for the reader study consisted of 120 randomly selected lesions in total (63 HCCs), while the remaining lesions were assigned to the training set. The time for the model from reading CT phases until classification of the lesion was recorded.

Statistics

Receiver operating characteristic (ROC) analyses were performed to calculate the area under curve (AUC) for evaluating model performance. The average accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for diagnosing each category were calculated. Student’s t-test (T-test) using IBM SPSS Statistics 26.0 was also performed to evaluate the statistical significance of differences in comparative studies.

Results

Figure 1 shows the flowchart of our study, including participant selection, model training, model testing, and reader study. A total of 479 participants (350 men and 129 women) were enrolled in our study. The mean age ± standard deviation at enrollment was 56 years ± 11. Summaries of included participants are described in Table 1.
Basic model and enhanced model

The diagnosis performances of the basic model and the enhanced model are shown in Table 3. Compared with the basic model, the enhanced model shows higher accuracy (17.30% higher in average, 91.68% vs. 74.38%, \( p < 0.001 \)), AUC (18.47% higher in average, 95.79% vs. 77.32%, \( p < 0.001 \)), sensitivity (12.06% higher in average, 94.60% vs. 82.54%, \( p = 0.029 \)), specificity (23.03% higher in average, 88.45% vs. 65.42%, \( p = 0.001 \)), PPV (17.34% higher in average, 90.03% vs. 72.69%, \( p < 0.001 \)), and NPV (15.45% higher in average, 93.77% vs. 78.32%, \( p = 0.008 \)).

The ROC curves of the basic and enhanced models with the corresponding AUC values are shown in Figure 3. The liver masses misdiagnosed by the basic model or enhanced model are shown in Figure 4. We present four-phase images of a 62-year-old man with a hemangioma and a 54-year-old man with an HCC. The major criterion of HCC such as “wash out” cannot be extracted by the model without the contrast-enhanced CT slices, which leads to the poor performance of the basic model.

MExPaLe model

In order to further improve the diagnosis, we first extracted the spatial morphological information of the local tumor during the data preprocessing process. Then, we added the patient’s age and gender information, which were automatically recorded in the medical system. We finally compared the average diagnosis accuracy of models with different extra information, as shown in Figure 5. The average accuracy of the MExPaLe model was 94.18%, which was higher than that of the enhanced model (91.68%), the enhanced model with spatial morphological information

| Parameter (%) | Basic model | Enhanced model | \( p \)-value* |
|---------------|-------------|----------------|--------------|
| Accuracy      | 74.38 (70.25–80.00) | 91.68 (86.67–95.87) | < 0.001      |
| AUC           | 77.32 (69.08–83.65) | 95.79 (92.93–98.09) | < 0.001      |
| Sensitivity   | 82.54 (69.84–95.24) | 94.60 (90.47–100.00) | 0.029        |
| Specificity   | 65.42 (53.45–95.24) | 88.45 (82.46–91.38) | 0.001        |
| PPV           | 72.69 (66.67–76.92) | 90.03 (85.07–92.64) | < 0.001      |
| NPV           | 78.32 (68.85–92.31) | 93.77 (88.67–100.00) | 0.008        |

AUC, area under curve; PPV, positive predictive value; NPV, negative predictive value. Data are median values in brackets and range in parentheses. *\( p \)-value for differences between basic model and enhanced model, calculated with Student’s t-test. The bold values show the significant differences between basic model and enhanced model.
the enhanced model with spatial morphological information and age (92.68%), and the enhanced model with spatial morphological information and sex (92.84%).

The diagnostic performance of the MExPaLe model compared with other authors is shown in Table 4. The MExPaLe model achieved an average accuracy of 94.18%, which was 4.99% higher than 2D CNN, 3.34% higher than 3D CNN, and 2.50% higher than 3D ResNet. Particularly, the MExPaLe model showed good performance in terms of specificity and NPV. The ROC curves of models are described in Figure 6A, and the confusion matrix of the MExPaLe model is described in Figure 6B. The MExPaLe model achieved an average AUC of 96.31%, which was 1.53% higher than 2D CNN, 0.31% higher than 3D CNN, and 0.52% higher than 3D ResNet.
ResNet. The average ratio of true positive was 98.10%, and the average ratio of true negative was 89.85%.

Reader study

In the reader study, classification of 120 randomly selected lesions by the MExPaLe model achieved an accuracy of 94.17% (113/120). Diagnosis accuracies by radiologists from the First Affiliated Hospital of Zhejiang University (radiologist 1) and from the community primary hospital (radiologist 2) on the same lesions were 90.83% (109/120) and 83.33% (100/120), respectively (Table 5). We then randomly divided the lesions into five equal parts using T-test for statistical comparisons between the radiologists and our proposed MExPaLe model. The p-values comparing the MExPaLe model and radiologists 1 and 2 were 0.018 and 0.002, respectively, suggesting significant differences. The average runtime analyzing each lesion was 0.13 s for the MExPaLe model on one Graphics Processing Unit, while for the radiologists, on average 30 s and 37.5 s were needed. ROC curves of our MExPaLe model and two radiologists are shown in Figure 7. The misdiagnosed cases of the model and radiologists are described in Table 6. The coincidence degree between the MExPaLe model and radiologist 1 was 16.67% for HCC masses and 10.00% for non-HCC masses, while with radiologist 2, the coincidence degree was 25.00% for HCC masses and 22.22% for non-HCC masses. Our model showed a lower misdiagnosis rate for HCC masses compared with the two radiologists. Moreover, the performance of our model was more stable than those of the radiologists, with radiologist 1 showing high misdiagnosis for HCC masses and radiologist 2 showing high misdiagnosis for non-HCC masses. Some representative masses with varying diagnostic results from the MExPaLe model and the two radiologists are shown in Figure 8. As shown in Figure 8B, 71.43% (5/7) of the misdiagnosed cases by the model were ICC masses being misdiagnosed as HCC masses. This also constitutes the majority of misdiagnoses by the radiologists since it is hard to differentiate HCC from ICC especially owing to the low incidence rate of ICC. Therefore, by increasing the cases of ICC to balance the dataset, the model performance can be improved in the future.
Discussion

In this work, we built a deep learning-based model, MExPaLe, for the diagnosis of liver tumor with typical images from four-phase CT and MEI, demonstrating high performance and excellent efficiency. The accuracy for diagnosing liver tumors of the proposed model and the two radiologists were 94.17% (113 of 120), 90.83% (109 of 120, \(p = 0.018\)), and 83.33% (100 of 120, \(p = 0.002\)), showing significant differences. The average time analyzing each lesion by our proposed MExPaLe model was 0.13 s, which was close to 250 times faster than that of both radiologists.

We used volumetric 3D CT patches as inputs. The 3D model can provide more relevant information to lesion classification, minimizing model variability, and it was not dependent on manual slice selection. Concerns for using the 3D model may involve possible expensive computational cost and time consumption. However, by focusing on local liver lesions and a relatively shallow model structure, we achieved sub-second runtime per case, taking four-phase CT volumetric scans as input, and therefore, it no longer becomes a practical obstacle.

In real clinical conditions, critical diagnostic features, such as hyper-enhancement and washout, are the main features used by radiologists. These features are obtained through the comparison of multi-phase CT images, necessitating the use of enhanced contrast agents to improve the diagnosis accuracy. This is also verified by our results obtained from the basic model and enhanced model, which had a median accuracy of 74.38% (range, 70.25%–80.00%) and 91.69% (range, 86.67%–95.87%), respectively, and by the statistical test.

Many works have confirmed that clinical data about the patients can improve the performance of diagnosis. However, the clinical data used in those works are often too complicated to obtain, and their processing requires additional manpower and material resources. More importantly, some clinical data can be inaccurate at the time of collection, such as family genetic history. Instead, our experiment requires only the basic information of the patient, i.e., age and gender, and minimal spatial morphological information lost during image preprocessing, which does not increase the clinical workload; therefore, it is of high practical value to be used in the clinics. The proposed MExPaLe model showed a median accuracy of 94.18% (range, 91.67%–96.67%) and a median AUC of 96.31% (range, 93.34%–98.22%). The MExPaLe model showed high specificity and NPV, attributed to the usefulness of the MEI in

| Parameter | MExPaLe model | Radiologist 1 | p-value* | Radiologist 2 | p-value* |
|-----------|---------------|---------------|----------|---------------|----------|
| Accuracy (%) | 94.17 (113/120) | 90.83 (109/120) | 0.018 | 83.33 (100/120) | 0.002 |
| Time | 0.13 s | 30 s | – | 37.5 s | – |

Radiologist 1 comes from the First Affiliated Hospital of Zhejiang University, and Radiologist 2 comes from a community primary hospital.

*p-value for differences between the MExPaLe model and radiologists, calculated with Student’s t-test.

The bold values show the best performance in terms of accuracy and time.
predicting liver tumor, which made the MExPaLe model more effective than others.

Furthermore, the MExPaLe model differs from previous works in that it does not require complex-shaped ROI tracing boundaries of tumors. The location and size of a 3D bounding box around the target lesion are enough in our work. We included 5-mm extra pixels surrounding the lesions to learn more peri-tumoral information, which is necessary for enhancing tumor differentiation. Additionally, it can reduce the possible subjective bias in the image capture process and maintain tumor size information to a certain extent.

The direct comparison between the MExPaLe model and the two radiologists suggests that the MExPaLe model can serve as a reliable and quick “second opinion” for radiologists. In the diagnosis of HCCs, the accuracy of the MExPaLe model was higher than that of the chief radiologist at a first-tier research hospital and the radiologist from a community primary hospital, both with statistical significances. Furthermore, the runtime of the MExPaLe model per case for liver tumor diagnosis was close to 250 times faster compared with the radiologists, suggesting that the use of the MExPaLe model can greatly improve the diagnosis throughput in the clinics.

While these results are promising, several limitations should be acknowledged regarding this study. Because of the limited number of imaging studies, we were restricted to a cross-validation experimental design. It would be better if we can incorporate an additional test dataset, and ideally an external dataset to consolidate the usefulness of our model in the clinical diagnosis of HCCs. Another limitation is that only four typical primary liver cancer types were available with the exclusion of other relevant cancers including metastatic liver cancers.

In conclusion, we proposed a model for the diagnosis of liver tumor. The MExPaLe model, which has incorporated four-phase CT volumes and the MEI, achieves the highest prediction accuracy of 94.18% (range, 91.67%–96.67%) and an AUC of 96.31% (range, 93.34%–98.22%). It is superior to both the basic model and the

| Parameter            | MExPaLe model | Radiologist 1 | Radiologist 2 |
|----------------------|---------------|---------------|---------------|
| Misdiagnoses         |               |               |               |
| HCC                  | 1             | 6             | 4             |
| Non-HCC              | 6             | 5             | 16            |
| Coincidence degree   |               |               |               |
| HCC                  | -             | 16.67% (1/6)  | 25.00% (1/4)  |
| Non-HCC              | -             | 10.00% (1/10) | 22.22% (4/6)  |

Radiologist 1 comes from the First Affiliated Hospital of Zhejiang University, and Radiologist 2 comes from a community primary hospital. HCC, hepatocellular carcinoma. The bold values mean the number of misdiagnosed masses for our model classification.
enhanced model. It is about 250 times more time-efficient compared with the radiologists for liver tumor diagnosis, taking only 0.13 s. The architectural design of the MExPaLe model may be applicable to more multi-phase CT-based diagnosis projects to provide high-quality patient care in a time-efficient manner.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

This study was reviewed and approved by Clinical Research Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

Author contributions

Literature research, YL. Project supervision, DK. Data annotation, ZP and XM. Experiment, YL. Clinical studies, YL, LX, ZP, XM, SG, ZC, JN, QL and SY. Data analysis, YL, LX, ZC, JN, QL and SY. Statistical analysis, YL. Manuscript writing, YL. Manuscript revision, LX, YL contributed equally to this work with SY. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the National Natural Science Foundation of China, Grant Nos. 12090020 and 12090025.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Rebecca LS, Kimberly DM, Ahmedin J. Tumor statistics 2019. CA Cancer J Clin (2019) 69(7–8). doi:10.3322/caac.21551

2. Freddie B, Jacques F, Isabelle S, Rebecca LS, Lindsey AT, Ahmedin J. Global tumor statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 tumors in 185 countries. CA Cancer J Clin (2018) 68:394–424. doi:10.3322/caac.21492

3. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecasis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatol (2018) 68:723–50. doi:10.1002/hep.29913

4. Tang A, Bashar MR, Corwin MT, Cruite I, Dietrich CF, Do RKG, et al. Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: A systematic review. Radiology (2018) 286:29–48. doi:10.1148/radiol.2017170554

5. Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, Garcia-Criado A, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol (2018) 101:72–81. doi:10.1016/j.ejrad.2018.01.025

6. Gilles RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology (2016) 278(2):563–77. doi:10.1148/radiol.2015151169

7. Acharya UR, Koh JE, Hagowara Y, Tan JH, Gertych A, Vijayananthan A, et al. Automated diagnosis of focal liver lesions using bidirectional empirical mode decomposition features. Comput Biol Med (2018) 94:11–8. doi:10.1016/j.compbiomed.2018.12.024

8. Xu X, Zhang H-L, Liu Q-P, Sun S-W, Zhang J, Zhu F-P, et al. Radiomic analysis of contrast-enhanced ct predicts microvascular invasion and outcome in hepatocellular carcinoma. Hepatol (2019) 70(6):1133–44. doi:10.1002/hep.29913

9. Kuzhervysh A, Sutishever I, Hinton G. ImageNet classification with deep convolutional neural networks. Communications of the ACM (2017). New York, NY, United States: IEEE (2017) 60(6): 84–90. doi:10.1145/3065386

10. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature (2015) 521(7553):436–44. doi:10.1038/nature14539

11. Aboutalib SS, Mohamed AA, Berg WA, Zuley ML, Sumkin JH, Wu SD. Deep learning to distinguish recalled but benign mammography images in breast cancer screening. Clin Cancer Res (2018) 24:5902–9. doi:10.1158/1078-0432.CCR-18-1115

12. Xi IL, Zhao Y, Wang R, Chang M, Purkayastha S, Chang K, et al. Deep learning to distinguish benign from malignant renal lesions based on routine MR imaging. Clin Cancer Res (2020) 26:1944–52. doi:10.1158/1078-0432.CCR-19-0374

13. Ozdemir O, Russell RL, Berlin AA. A 3D probabilistic deep learning system for detection and diagnosis of lung cancer using low-dose CT scans. IEEE Trans Med Imaging (2019) 39(5):1419–29. doi:10.1109/TMI.2019.2947595

14. Gulshan V, Peng L, Coram M, Stumpe MC, Wu D, Narayanaswamy A, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA-Journal Am Med Assoc (2016) 316:2402–10. doi:10.1001/jama.2016.17216

15. Esteva A, Kupel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature (2017) 542:1145–+. doi:10.1038/nature21056
16. Koizumi Y, Hirohata A, Osumi A, Shigeru K. Deep learning with convolutional neural network for differentiation of liver masses at dynamic contrast-enhanced CT: A preliminary study. *Radiol* (2018) 286:887-96. doi: 10.1148/radiol.2017170706

17. Todoroki Y, Iwamoto Y, Lin L, Hu H, Chen Y-W. Automatic detection of focal liver lesions in multi-phase CT images using a multi-channel & multi-scale CNN, conference proceedings. Annual international conference of the IEEE engineering in medicine and biology society. *IEEE Eng Med Biol Soc Annu Conf* (2019) 2019:872-5. doi: 10.1109/EMBC.2019.8857292

18. Frid-Adar M, Klang E, Arnaut M, Goldberger J, Greenspan H. Synthetic data augmentation using GAN for improved liver lesion classification. In: 2018 IEEE 15th international symposium on biomedical imaging, Washington, DC, USA: IEEE (2018). p. 289-93. doi: 10.1109/ISBI.2018.8363576

19. Liang D, Lin LF, Hu HJ, Zhang QW, Chen QQ, Iwamoto Y, et al. Combining convolutional and recurrent neural networks for classification of focal liver lesions in multi-phase CT images. In: *Med image computing comput assisted intervention - miccai 2018*, vol. Pt II. (2018). Springer, Cham p. 666-75. doi: 10.1007/978-3-030-09934-2_74

20. Raipurkar P, Irvin J, Ball RL, Zhu K, Yang B, Mehta H, et al. Deep learning for chest radiograph diagnosis: A retrospective comparison of the CheXNeXt algorithm to practicing radiologists. *PloS Med* (2018) 15:e1002686. doi: 10.1371/journal.pmed.1002686

21. Hamm CA, Wang CJ, Savic LJ, Ferrante M, Schobert I, Schlachter T, et al. Deep learning for liver tumor diagnosis part I: development of a convolutional neural network classifier for multi-phasic MRI. *Eur Radiol* (2019) 29:3338-47. doi: 10.1007/s00330-019-06205-9

22. Song Y, Yu Z, Zhou T, Teoh JYC, Lei B, Choi KS, et al. Learning 3d features with 2d cnns via surface projection for ct volume segmentation. In: *MICCAI*, Springer, Cham (2020). p. 176-86. doi: 10.1007/978-3-030-59719-1_18

23. Carreira J, Zisserman A. Quo vadis, action recognition? A new model and the kinetics dataset. In: *2017 IEEE Conference on Computer Vision and Pattern Recognition*, Honolulu, HI, USA: IEEE (2017). p. 6299–308. doi: 10.1109/CVPR.2017.502

24. Hara K, Kataoka H, Sato Y. Can spatiotemporal 3d cnns retrace the history of 2d cnns and imagenet? In: 2018 IEEE Conference on Computer Vision and Pattern Recognition. Salt Lake City, UT, USA: IEEE (2018). p. 6546-55. doi: 10.1109/CVPR.2018.00685

25. Zhou J, Wang W, Lei B, Ge W, Huang Y, Zhang L, et al. Automatic detection and classification of focal liver lesions based on deep convolutional neural networks: a preliminary study. *Front Oncol* (2021) 10:581210. doi: 10.3389/fonc.2020.581210

26. He K, Zhang X, Ren S, Sun J. Deep residual learning for image recognition. In: *2016 IEEE Conference on Computer Vision and Pattern Recognition*. Las Vegas, NV, USA: IEEE (2016). p. 770-8. doi: 10.1109/CVPR.2016.90

27. Liu R, Pan D, Xu Y, Zeng H, He Z, Lin J, et al. A deep learning-machine learning fusion approach for the classification of benign, malignant, and intermediate bone tumors. *Eur Radiol* (2021) 32:1371-83. doi: 10.1007/s00330-021-08195-z

28. Gao R, Zhao S, Aishanjiang K, Cai H, Wei T, Zhang Y, et al. Deep learning for differential diagnosis of malignant hepatic tumors based on multi-phase contrast-enhanced CT and clinical data. *J Hematol Oncol* (2021) 14(1):1–7. doi: 10.1186/s13045-021-01167-2

29. Johnson P. Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. *Gastroenterol Hepatol* (1999) 14:32–6. doi: 10.1046/j.1440-1746.1999.01873.x

30. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterol* (2012) 142:1264–73. doi: 10.1053/j.gastro.2011.12.061

31. Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. *Gastroenterol* (2018) 155:1828–37. doi: 10.1053/j.gastro.2018.08.024

32. Bosch FX, Ribes J, Diaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. *Gastroenterol* (2004) 127:5–16. doi: 10.1053/j.gastro.2004.09.011

33. Wu EM, Wong LL, Hernandez BY, Ji J-F, Jia W, Kwee SA, et al. Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. *Hepatoma Res* (2018) 4:66. doi: 10.20517/2394-5079.2018.87

34. Janesvka D, Chaloska-Ivanova V, Janevski V. Hepatocellular carcinoma: risk factors, diagnosis and treatment. *Open Access Maced J Med Sci* (2015) 3:732. doi: 10.3889/oamjms.2015.111

35. Peng J, Wang J, Kong D. A new convex variational model for liver segmentation. Proceedings of the 21st International Conference on Pattern Recognition. Tsukuba, Japan: IEEE (2012).